Microscopic Polyangiitis MarketRegional Analysis
EuropeMicroscopic Polyangiitis Market is expected to witness significant growthover the forecast period, owing to proposed product launches. For instance,Bristol-Myers Squibb Company is conducting phase lll clinical trials forAbatacept (Orencia), which is expected to be completed by September 2022.Orencia is a recombinant protein, which inhibits the T lymphocyte activationpathway, thereby suppressing the immune system.
Microscopic polyangiitis (MPA)occurs due to inflammation of blood vessels resulting in damage to otherorgans, mostly kidney, lungs, nerves, skin, and joints. MPA is an immune systemmediated disorder, however the exact reason leading to immune system dysfunctionis unknown. Since MPA affects multiple organs, various symptoms such asillness, fatigue, fever, loss of weight and appetite, coughing blood in case oflungs, and loss of sensation in case of nerves can be seen. Diagnosis involvesblood test for antineutrophil cytoplasmic antibodies (ANCA), urine test fordetection of red blood cells (RBCs), and imaging techniques such as computedtomography (CT), magnetic resonance (MR) scan, and X-rays. If results of thesetests are positive for presence of MPA, biopsy (tissue sample testing) isperformed for confirmation of presence of MPA.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2529
Microscopic Polyangiitis MarketDrivers
In the recent past, variousregulatory bodies such as European Medicines Agency (EMA), the U.S. Food andDrug Administration (FDA), Medicines and Healthcare products Regulatory Agency(MHRA), and others have granted treatment related approvals. Such treatmentapprovals are expected to propel the global microscopic polyangiitis marketgrowth over the forecast period. For instance, in October 2018, Genentech,Inc., a San Francisco-based biotechnology company, received approval from theU.S. Food and Drug Administration (FDA) to update the Rituxan label to includethe follow-up treatment information of adult patients suffering fromgranulomatosis with polyangiitis and microscopic polyangiitis, who had shownimprovement in medical condition with the glucocorticoid and cyclophosphamideinduction treatment.
Launch of new treatment methodsby key players is expected to drive the global microscopic polyangiitis marketgrowth over the forecast period. For instance, in July 2018, InflaRx N.V., aGerman clinical stage bio-pharmaceutical company, received an approval from theU.S. Food and Drug Administration (FDA) for conducting phase-2 clinical trialsto assess the safety and effectiveness of IFX-1 for treatment ofanti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis, presence of whichindicates that the patient is suffering from microscopic polyangiitis. IFX-1 isan inhibitor of the complement system (a component of immune system) andneutralizes C5a component without affecting the normal immune functions. These factorsare expected to drive the global microscopic polyangiitis market growth overthe forecast period.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/microscopic-polyangiitis-market-2529
Microscopic Polyangiitis MarketRestraints
The corticosteroids have sideeffects, which include skin thinning and intense pain. The monoclonal antibodyproduction involves costly and time consuming research. Azathioprine involvesside effects such as diarrhea, joint pain, loss of coordination, seizure, andvision changes. These factors are expected to restrain the global microscopicpolyangiitis market growth over the forecast period.
In March 2018, AmerigenPharmaceuticals Limited, a China-based generic pharmaceutical company, wasgranted approval for its Abbreviated New Drug Application (‘ANDA’), by the U.S.FDA, for its cyclophosphamide capsules 25mg and 50mg. Cyclophosphamide is animmunosuppressive agent used for the treatment of microscopic polyangiitis incombination with corticosteroids. This is expected to propel the Asia Pacificmicroscopic polyangiitis market growth over the forecast period in turnsupporting global microscopic polyangiitis market growth.
Microscopic Polyangiitis MarketKey Players
Some of the key players operatingin the global microscopic polyangiitis market include Genentech, Inc.,Celltrion, Inc., InflaRx N.V., ChemoCentryx Inc., Bristol-Myers Squibb Company,Teijin Pharma Ltd, Amerigen Pharmaceuticals Limited, Sandoz International GmbH(Novartis Division), and TTY Biopharm Company Ltd.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2529
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
